INTERNATIONAL FLAVORS & FRAGRANCES INC
For the period ended Aug 5, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 5, 2025 · Filed Aug 5, 2025
Contents
EX-99.1 · Comparable Reportable Segment Performance
Comparable Reportable Segment Performance
The following information and schedule provides reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedule is not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net Sales | ||||
| Taste(1) | $631 | $603 | $1,258 | $1,218 |
| Food Ingredients | 850 | 847 | 1,646 | 1,703 |
| Health & Biosciences | 577 | 556 | 1,117 | 1,085 |
| Scent(2) | 603 | 603 | 1,217 | 1,221 |
| Pharma Solutions(3) | 103 | 87 | 369 | 337 |
| Consolidated | $2,764 | $2,696 | $5,607 | $5,564 |
| Segment Adjusted Operating EBITDA(5) | ||||
| Taste(1) | $125 | $123 | $256 | $238 |
| Food Ingredients | 124 | 107 | 235 | 215 |
| Health & Biosciences | 151 | 149 | 289 | 287 |
| Scent(2) | 130 | 141 | 274 | 295 |
| Pharma Solutions(3) | 22 | 22 | 76 | 69 |
| Total | 552 | 542 | 1,130 | 1,104 |
| Depreciation & Amortization | (242) | (246) | (478) | (524) |
| Interest Expense | (61) | (79) | (132) | (162) |
| Other Expense, net | (10) | (15) | (30) | (16) |
| Restructuring and Other Charges | (21) | (2) | (38) | (5) |
| Impairment of Goodwill | — | (64) | (1,153) | (64) |
| (Losses) Gains on Business Disposals | (81) | 368 | (81) | 368 |
| Loss on Assets Classified as Held for Sale | — | (282) | — | (282) |
| Divestiture and Integration Costs | (26) | (59) | (77) | (117) |
| Strategic Initiatives Costs | (6) | (12) | (14) | (16) |
| Regulatory Costs | (53) | (19) | (64) | (54) |
| Gain on Debt Extinguishment | 488 | — | 488 | — |
| Entity Realignment Costs | (4) | (2) | (5) | (3) |
| Other | (2) | 7 | (6) | 7 |
| Impact of Business Divestitures(4) | — | 46 | — | 62 |
| Income (Loss) Before Taxes | $534 | $183 | $(460) | $298 |
| Segment Adjusted Operating EBITDA Margin(5) | ||||
| Taste | 19.8% | 20.4% | 20.3% | 19.5% |
| Food Ingredients | 14.6% | 12.6% | 14.3% | 12.6% |
| Health & Biosciences | 26.2% | 26.8% | 25.9% | 26.5% |
| Scent | 21.6% | 23.4% | 22.5% | 24.2% |
| Pharma Solutions | 21.4% | 25.3% | 20.6% | 20.5% |
| Consolidated | 20.0% | 20.1% | 20.2% | 19.8% |
(1)Taste sales and segment adjusted operating EBITDA information exclude the results of the Flavors & Essences UK business that was divested on September 1, 2024, to present fully comparable scenarios.
(2)Scent sales and segment adjusted operating EBITDA information exclude the results of the Cosmetic Ingredients business that was divested on April 2, 2024, to present fully comparable scenarios.
(3)Pharma sales and segment adjusted operating EBITDA information exclude the results of the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively, to present fully comparable scenarios.
(4)Amounts exclude the results of the Flavors & Essences UK business that was divested on September 1, 2024, the Cosmetic Ingredients business that was divested on April 2, 2024, and the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively, to present fully comparable scenarios.
(5)Following the completed divestitures of the Pharma Solutions disposal group on May 1, 2025 and the Nitrocellulose business on May 9, 2025, the Company reallocated certain corporate costs previously attributed to the Pharma Solutions segment. These costs have been redistributed across the Taste, Food Ingredients, Health & Biosciences, and Scent segments to align with the updated 2025 operating model.
| Selling & Administrative Expenses | Research & Development Expenses | Total EBITDA Impact | |
|---|---|---|---|
| Taste | $2 | $— | $(2) |
| Food Ingredients | 2 | — | (2) |
| Health & Biosciences | 1 | 1 | (2) |
| Scent | 1 | 1 | (2) |
| Total | $6 | $2 | $(8) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.